http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-40794-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_600db5b93a54999d3db277d10725d525 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate | 1975-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1979-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-40794-B1 |
| titleOfInvention | Influenza vaccines |
| abstract | 1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4‹C to 37‹C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.n[GB1498261A] |
| priorityDate | 1974-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.